ABUS Stock — Arbutus Biopharma Corporation: Cash, EV, Pipeline

What they do

Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV).

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.65

Market cap

$560.2M

Cash

$92.6M

Enterprise value

$467.6M

Balance sheet

Cash	$92.6M
Debt	$0.0M
Net cash	$92.6M
Enterprise value	$467.6M
Basic shares	197.8M shares
Fully diluted shares	212.4M shares
Fully diluted market cap	$775.1M
Cash per share	$0.47
Quarterly burn	$6.0M
Cash runway	15.4 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

197.8M

Pre-funded warrants

0.0M

Options

12.4M

RSUs

1.5M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.6M

FDSO

212.4M

Cap table as of 2026-08-10.

Price history

Loading ABUS daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

Imdusiran

Phase 2 · Active Modality: GalNAc-conjugated subcutaneously-delivered RNAi therapeutic

Aliases AB-729

Target HBV antigens (including HBsAg)

Partnerships Barinthus Biotherapeutics (IM-PROVE II collaboration, completed; Phase 2b not pursued); Qilu Pharmaceutical (license terminated June 2025, global rights returned to Arbutus)

Indications

chronic hepatitis B (cHBV) (Phase 2)

Status note Two Phase 2a trials (IM-PROVE I, IM-PROVE II) completed; Qilu partnership terminated with global rights returned to Arbutus; Phase 2b combination with VTP-300 not pursued after Barinthus postponed VTP-300 development; discovery operations ceased but clinical program active.

AB-101

Phase 1 · Active Modality: oral small-molecule PD-L1 inhibitor

Target PD-L1

Indications

chronic hepatitis B (cHBV) (Phase 1)

Status note Phase 1 trial in healthy subjects; FDA clinical hold on IND; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06277037	Not disclosed	Recruiting	Sponsor	ABUS	—	Long Term Follow-up	—
NCT06154278	Phase 2	Recruiting	Collaborator	University of Maryland, Baltimore	—	Chronic Hepatitis B	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Arbutus Biopharma Corporation on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	1,268,147	-1,865,028	0.29%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ABUS — Arbutus Biopharma Corporation ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

ABUS — Arbutus Biopharma Corporation